Sartorius Stedim Biotech provides earnings guidance for the full year 2022. The company expects Sales revenue to increase by 14% to 18% with sustained high profitability.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
192.6 EUR | +0.21% | -2.16% | -19.60% |
16/05 | Sartorius sinks again towards year low | DP |
16/05 | Transcript : Sartorius Stedim Biotech S.A., Sartorius Aktiengesellschaft - Analyst/Investor Day |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.60% | 2.03TCr | |
-5.56% | 18TCr | |
-0.11% | 11TCr | |
-6.17% | 6.61TCr | |
+2.64% | 5.07TCr | |
+6.58% | 4.37TCr | |
+4.91% | 4.13TCr | |
+21.98% | 3.16TCr | |
+14.45% | 2.5TCr | |
-5.81% | 2.42TCr |
- Stock Market
- Equities
- DIM Stock
- News Sartorius Stedim Biotech
- Sartorius Stedim Biotech Provides Earnings Guidance for the Full Year 2022